Drug price transparency laws enable state policymakers to understand opaque drug pricing and payment systems to formulate appropriate policy solutions to high prices, while also creating the data infrastructure to effectively realize those policy solutions. Since Vermont passed the first state drug price transparency law in 2016, more than a dozen states have enacted and […]
Author Archive for: johanna-butler
About Johanna Butler
Johanna Butler joined NASHP’s Coverage, Cost, and Value team in June 2018. She is involved with several projects related to lowering the cost of health care, focusing specifically on health system costs and prescription drug prices. She has also worked on advancing evidence-based policymaking through patient-centered outcomes research. Prior to joining NASHP, Johanna was an intern in the ranking member’s health policy office of the Senate Committee on Health, Education, Labor, and Pensions. She has also worked as the Lloyd Meeds Policy Fellow at K&L Gates and interned in the White House Office of Cabinet Affairs. Johanna graduated from American University in 2018 with an interdisciplinary studies degree focused on communications, law, economics, and government, and holds a certificate in Advanced Leadership Studies from the School of Public Affairs.
Entries by Johanna Butler
High prices for health care services and prescription drugs are driving health care spending and increasing insurance premiums. To tackle rising health care costs, states have advanced two separate but related initiatives over the past few years: cost-growth benchmarks to track and contain overall health care spending; and prescription drug affordability boards (PDABs) to conduct […]
Facing rising health care costs and increased consolidation of hospitals and provider groups into large health systems, states are exploring ways to contain costs and provide oversight of the growing market power of large hospitals. Through model policies from the National Academy for State Health Policy (NASHP), states can leverage their existing health market authority […]
Democrats in the US House of Representatives recently reintroduced their comprehensive prescription drug pricing reform bill, HR 3, and held hearings on drug pricing. However, prospects for enacting this legislation remains uncertain. In the meantime, states are moving forward with their own efforts to lower drug costs, many of which align with provisions in HR 3. First passed by the House in December 2019, HR 3 includes provisions that would, among other things: Allow the US Department of […]
Amid the coronavirus pandemic, state officials have continued to plan for and address another looming public health crisis – climate change. In recognition of Earth Day, the National Academy for State Health Policy (NASHP) interviewed state officials to learn how they are preparing for the health impacts of climate change. The interviews revealed a wealth […]
Rampant consolidation in nearly every state has created dominant health care systems that can use anticompetitive contracting practices to charge supracompetitive prices, especially to commercial insurance plans.
A new, independent analysis of the Montana state employee health plan’s transition to reference-based pricing – which limits hospital prices to a multiple of what Medicare pays – found significant savings for the state in the two years after its implementation. Further, there is no evidence that utilization artificially increased as a result of the new payment […]
In addition to providing critical funding for state COVID-19 response efforts, the American Rescue Plan requires drug manufacturers to pay more in Medicaid rebates for drugs with large price increases. This change, effective in 2024, has the potential to generate significant federal and state savings.
As states take important steps to lower prescription drug costs, at least six have implemented prescription drug affordability review initiatives, although approaches vary across states. The National Academy for State Health Policy (NASHP)’s new chart, Comparison of State Prescription Drug Affordability Review Initiatives, provides a road map of the diverse efforts taken by Maryland, Maine, […]